Can Bicara (BCAX) Commercialize Ficera? Breakthrough 3-Year Data Faces Execution Risk in C-Suite Overhaul
On August 11, Bicara Therapeutics (NASDAQ:BCAX) used its second-quarter earnings call to deliver two headlines at once.
Bicara Therapeutics Inc. (BCAX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 7,255,993 | $215,430,432 | 1.87% | |
| 2. | Siren L.L.C. Raymond Debbane | 5,602,970 | $166,352,179 | -4% | 3.37% |
| 3. | Vestal Point Capital Ryan Wilder | 5,250,000 | $155,872,500 | -4% | 3.64% |
| 4. | Deep Track Capital David Kroin | 4,100,000 | $121,729,000 | +1% | 1.77% |
| 5. | Palo Alto Investors William Leland Edwards | 550,408 | $16,341,614 | 2.26% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $16.00 | 300,000 | $4,800,000.00 | 4,603,418 | 2026-02-26 | Filing | |
| $18.00 | 152,480 | $2,744,640.00 | 2,652,575 | 2024-09-16 | Filing | |
| $18.00 | 1,680,520 | $30,249,360.00 | 4,303,418 | 2024-09-16 | Filing | |
| $18.00 | 35,000 | $630,000.00 | 897,587 | 2024-09-17 | Filing | |
| $18.00 | 35,000 | $630,000.00 | 897,587 | 2024-09-17 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $23.43 | 3,442 | $80,662.93 | 181,641 | 2026-09-08 | Filing | |
| $22.77 | 14,058 | $320,052.86 | 185,083 | 2026-09-08 | Filing | |
| $27.97 | 12,500 | $349,591.25 | 129,855 | 2026-08-10 | Filing | |
| $27.98 | 10,000 | $279,750.00 | 362,152 | 2026-08-10 | Filing | |
| $27.98 | 18,750 | $524,533.13 | 181,641 | 2026-08-10 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,848,090 | $114,249,784 | 0% | |
| 2. | 3,171,015 | $93,957,174 | 0.04% | |
| 3. | 3,163,517 | $93,924,820 | 63.77% | |
| 4. | 3,010,425 | $89,379,518 | 1.79% | |
| 5. | 2,216,639 | $65,812,012 | 0% |
News See All
Bicara Therapeutics Inc. Common Stock (NASDAQ:BCAX) Q1 2026 Earnings Call Transcript
Bicara Therapeutics Inc. Common Stock (NASDAQ:BCAX) Q1 2026 Earnings Call Transcript May 11, 2026Bicara Therapeutics Inc. Common Stock misses on earnings expectations.
Bicara Therapeutics Inc. Common Stock (NASDAQ:BCAX) Q4 2025 Earnings Call Transcript
Bicara Therapeutics Inc. Common Stock (NASDAQ:BCAX) Q4 2025 Earnings Call Transcript March 30, 2026 Operator: Good day, and thank you for standing by.
Morgan Stanley Maintains Buy Rating on Bicara (BCAX) After the Ficerafusp Alfa Trial Update
On May 23, Judah Frommer from Morgan Stanley maintained a Buy rating on Bicara Therapeutics Inc. (NASDAQ:BCAX) while keeping the price target at $36.
Stifel Reaffirms Buy Rating on BCAX After Promising ASCO Data for HPV-Negative Patients
On May 24, analysts at Stifel reaffirmed their Buy rating and price target of $48 for Bicara Therapeutics Inc. (NASDAQ:BCAX).